Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer.
Jason J ZoellerAleksandr VagodnyVeerle W DanielsKrishan TanejaBenjamin Y TanYoko S DeRoseMaihi FujitaAlana L WelmAnthony LetaiJoel D LeversonVincent BlotRoderick T BronsonDeborah A DillonJoan S BruggePublished in: Breast cancer research : BCR (2020)
The dramatic tumor regressions achieved using combined agents in pre-clinical TNBC models underscore the abilities of BCL-2/XL antagonists to enhance the effectiveness of EGFR-targeted ADCs and highlight the clinical potential for usage of such targeted ADCs to alleviate toxicities associated with combinations of BCL-2/XL inhibitors and systemic chemotherapies.